PEDIATRIX MEDICAL GROUP, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.31 USD | -0.68% |
|
-2.01% | -21.40% |
| May. 07 | Transcript : Pediatrix Medical Group, Inc., Q1 2024 Earnings Call, May 07, 2024 | |
| May. 07 | Earnings Flash (MD) PEDIATRIX MEDICAL GROUP Posts Q1 Revenue $495.1M, vs. Street Est of $500.4M | MT |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Its low valuation, with P/E ratio at 8.1 and 7.24 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The stock, which is currently worth 2024 to 0.51 times its sales, is clearly overvalued in comparison with peers.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company does not generate enough profits, which is an alarming weak point.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -21.40% | 605M | B | ||
| +25.52% | 88.99B | C+ | ||
| -24.52% | 74.82B | B- | ||
| +0.49% | 26.63B | C+ | ||
| +4.31% | 17.88B | A- | ||
| -14.25% | 16.43B | B | ||
| +2.97% | 15.77B | A- | ||
| +79.20% | 13.21B | C+ | ||
| +70.11% | 13.08B | C- | ||
| +40.44% | 12.9B | B- |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- MD Stock
- Ratings Pediatrix Medical Group, Inc.
